BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 32048750)

  • 21. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
    Xu X; Zhang Y; Jasper J; Lykken E; Alexander PB; Markowitz GJ; McDonnell DP; Li QJ; Wang XF
    Oncotarget; 2016 Apr; 7(15):20381-94. PubMed ID: 26967387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression.
    Kong Y; Yang L; Wei W; Lyu N; Zou Y; Gao G; Ou X; Xie X; Tang H
    Epigenomics; 2019 Aug; 11(10):1163-1176. PubMed ID: 31337246
    [No Abstract]   [Full Text] [Related]  

  • 26. Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.
    Ou-Yang F; Pan MR; Chang SJ; Wu CC; Fang SY; Li CL; Hou MF; Luo CW
    Life Sci; 2019 Dec; 238():116963. PubMed ID: 31639396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
    Sheng J; Xue X; Jiang K
    Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SALL4 promotes tumor progression in breast cancer by targeting EMT.
    Chen T; Tsang JYS; Su XC; Li P; Sun WQ; Wong ILK; Choy KY; Yang Q; Tse GMK; Chan TH; Chow LMC
    Mol Carcinog; 2020 Oct; 59(10):1209-1226. PubMed ID: 32835442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.
    Shao Z; Ma X; Zhang Y; Sun Y; Lv W; He K; Xia R; Wang P; Gao X
    Mol Carcinog; 2020 May; 59(5):533-544. PubMed ID: 32181526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA WT1-AS Inhibits Triple-Negative Breast Cancer Cell Migration and Invasion by Downregulating Transforming Growth Factor β1.
    Wang J; Xi C; Yang X; Lu X; Yu K; Zhang Y; Gao R
    Cancer Biother Radiopharm; 2019 Dec; 34(10):671-675. PubMed ID: 31621381
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
    Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C
    Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF-β2 expression.
    Kim S; Han J; Jeon M; You D; Lee J; Kim HJ; Bae S; Nam SJ; Lee JE
    Tumour Biol; 2016 Aug; 37(8):11397-407. PubMed ID: 26984157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
    Zheng S; Li M; Miao K; Xu H
    J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-5590-3p-YY1 feedback loop promotes the proliferation and migration of triple-negative breast cancer cells.
    Liang F; Fu X; Wang L
    J Cell Biochem; 2019 Oct; 120(10):18415-18424. PubMed ID: 31190375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams.
    Cammarata FP; Forte GI; Broggi G; Bravatà V; Minafra L; Pisciotta P; Calvaruso M; Tringali R; Tomasello B; Torrisi F; Petringa G; Cirrone GAP; Cuttone G; Acquaviva R; Caltabiano R; Russo G
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling.
    Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T
    Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
    Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
    Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.